The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.